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Inflammation is a crucial part of innate immune responses but, if imbalanced, can lead to serious clinical conditions or even
death. Cytokines regulate inflammation, and studies report their impact on clinical outcome. However, host and pathogen ge-
netic backgrounds influence cytokine production, making it difficult to evaluate which inflammatory profiles (if any) relate to
improved prognosis. Streptococcus pneumoniae is a common human pathogen associated with asymptomatic nasopharyngeal
carriage. Infrequently, it can lead to a wide range of diseases with highmorbidity andmortality rates. Studies show that both
pneumococcal serotype and host genetic background affect the development of disease and contribute to variation in inflamma-
tory responses. In this study, we investigated the impact of the host and pneumococcal genetic backgrounds on pulmonary cyto-
kine responses and their relationship to animal survival. Two inbred mouse strains, BALB/c and CBA/Ca, were infected with 10
pneumococcal strains, and the concentrations of six pulmonary cytokines were measured at 6 h and 24 h postinfection. Collected
data were analyzed by principal-component analysis to identify whether there is any pattern in the observed cytokine variation.
Our results show that host-pneumococcus combination was at the core of observed variation in cytokine responses, yet the re-
sulting cytokine profile discriminated only between survivors and fatalities but not mouse or pneumococcal strains used during
infection. Therefore, our results indicate that although alternative inflammatory profiles are generated during pneumococcal
infection, a common pattern emerged, which determined the clinical outcome of pneumococcal infections.
Streptococcus pneumoniae is an important human pathogen as-sociated with a wide range of diseases and high mortality and
morbidity rates (1, 2). Studies show that pneumococcal serotype
and host genetic background are the major factors in the develop-
ment of pneumococcal disease (3–5). Pneumococcal infections
are characterized by an inflammatory response whether or not the
outcome is a disease. The mortality from pneumococcal disease is
often linked to imbalanced inflammation, and deaths are reported
despite successful pathogen clearance (6, 7). During pneumococ-
cal disease, antibiotic treatments can exacerbate inflammation
due to a rapid release of highly proinflammatory bacterial prod-
ucts (8). Therefore, adjuvant anti-inflammatory therapies are fre-
quently used to support treatment of severe pneumococcal disease
cases, but their clinical relevance is often disputed (7, 9, 10).
Cytokines are key players during pneumococcal infection, but
which inflammatory profile constitutes a protective or patholog-
ical response or the contribution of host and pneumococcal ge-
netics to the observed response is unclear. The inherent variation
in cytokine profiles due to the host and pneumococcal genetic
backgrounds is a particularly confounding factor. For example,
differences seen in cytokine concentrations in BALB/c mice de-
pend on the pneumococcal strain used but were not associated
with animal mortality (11). Similarly, a panel of inbred mouse
strains showed highly diverse cytokine responses to lipopolysac-
charide (LPS) treatment, but again, no significant relationship
with animal survival was reported (12). These observations sug-
gest that the variation in inflammatory profiles stems from host
and pathogen genetic diversity rather than clinical outcome.
However, the impact of inflammatory mediators on the develop-
ment of pneumococcal pneumonia is well documented (13–17),
as is the relationship between genetic polymorphisms in cytokine
genes and susceptibility to pneumonia, sepsis, and otitis media,
which are caused by S. pneumoniae infection (18–22). It has also
been shown that immunomodulation contributes to the protec-
tive effect of pneumococcal colonization and improves survival
during disease (23, 24), supporting the contribution of cytokines
to mortality and morbidity. However, the pleiotropic and redun-
dant nature of cytokine responses suggests that cytokine-cytokine
interactions rather than their absolute concentrations may deter-
mine the progress of pneumococcal disease.
In this study, a large number of different pneumonia pheno-
Received 15 August 2015 Returned for modification 8 September 2015
Accepted 23 December 2015
Accepted manuscript posted online 19 January 2016
Citation Jonczyk MS, Escudero L, Sylvius N, Norman M, Henriques-Normark B,
Andrew PW. 2016. Variation in inflammatory response during pneumococcal
infection is influenced by host-pathogen interactions but associated with animal
survival. Infect Immun 84:894–905. doi:10.1128/IAI.01057-15.
Editor: L. Pirofski
Address correspondence to Magda S. Jonczyk,
magdalena.jonczyk@nottingham.ac.uk, or Peter W. Andrew, pwa@leicester.ac.uk.
* Present address: Magda S. Jonczyk, SBRC, University of Nottingham, Nottingham,
United Kingdom; Laura Escudero, Institute of Cancer and Genetics, Cardiff
University School of Medicine, Cardiff, United Kingdom.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/IAI.01057-15.
Copyright © 2016 Jonczyk et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution 4.0 International license.
crossmark
894 iai.asm.org April 2016 Volume 84 Number 4Infection and Immunity
 o
n
 August 22, 2017 by CARDIFF UNIVERSITY
http://iai.asm
.org/
D
ow
nloaded from
 
types were generated to evaluate the contribution of the host and
pneumococcal genetic backgrounds to the clinical outcome of
pneumonia. Our results demonstrate that pneumococcal lethality
and host susceptibility to infection are influenced by the host-
pathogen combination. The observed variation in pneumonia
phenotypes was associated with an extensive variation in the pul-
monary transcriptome and pulmonary cytokine responses. Using
multivariate data analysis tools, we were able to discriminate be-
tween survivors and fatalities of pneumococcal infection based on
the observed pulmonary cytokine profile, therefore indicating the
protective or pathological character of lung inflammation.
MATERIALS AND METHODS
Ethics statement. Experiments using laboratory animals were conducted
at designated University of Leicester facilities in compliance with United
Kingdom Home Office license PPL 60/4327. The study was approved by
the University of Leicester Ethics Committee and adhered to United King-
dom Use of Animals Act guidance.
Mice. Female BALB/cOlaHsd (BALB/c) and CBA/CaOlaHsd (CBA/
Ca) mice were obtained from Harlan, United Kingdom, and housed at the
Division of Biomedical Services at the University of Leicester. C57BL/6J
mice were obtained from Charles River and housed in animal facilities of
the Department of Clinical Microbiology, Karolinska University Hospital,
Solna, Sweden. Mice were kept in controlled environmental facilities and
fed a fundamental diet. The experiments were performed on mice at the
age of 9 to 12 weeks.
Bacterial strains. Ten Streptococcus pneumoniae strains were used in
this study: two serotype 3 (ST3) strains (SP3-BS71 [25] and BHN35 [26]),
two serotype 6B strains (BHN418 and BHN191), three serotype 19F
strains (BHN100, LgtSt215, and CBR206), one serotype 4 strain (TIGR4),
one serotype 2 strain (D39), and one serotype 14 strain (Sp14-BS69 [25])
(Table 1). An infectious dose of each bacterial strain was prepared as
previously described (5). Briefly, pneumococcal strains were incubated
overnight on blood agar base (BAB) with 5% (vol/vol) horse blood at 37°C
in a CO2-enriched atmosphere. Sweeps of colonies were then used to
inoculate Todd-Hewitt broth supplement with yeast extract (THY) (BD)
until the optical density at 600 nm (OD600) of the suspension reached 0.2.
Next, the culture was inoculated into fresh THY medium at a dilution of
1:100. The growth of the bacteria was monitored until the culture reached
mid-exponential phase (OD600 corresponding to 1  10
8 to 3  108
CFU/ml). At this point, the culture was mixed with glycerol to a final
concentration of 10% (vol/vol) and stored at70°C until further use.
Infection. Mice were infected as described previously (5). Briefly, the
challenge culture containing 1  108 to 3  108 CFU/ml was defrosted
and centrifuged at 13,000 rpm, the supernatant was removed, and the
pellet was resuspended in phosphate-buffered saline (PBS). An infectious
dose at a concentration of 2 106 CFU in 20 l was administered intra-
nasally to lightly anesthetized animals (2.5% [vol/vol] fluothane [Zeneca
Pharmaceuticals, United Kingdom] over oxygen at a rate of 1.5 to 2 liters/
min). Infected animals were then monitored every 6 h to 10 h for clinical
signs until animal expiration, either when the animal was lethargic or, for
survivors, at the end of the experiment, 168 h postinfection. A clinical
score of 1 denoted a lack of clinical signs, a score of 2 indicated a slightly
hunched animal, a score of 3 indicated a hunched animal with a starey
coat (which refers to a dry hair coat where the hair appears to be standing
on end or disturbed, indicating a lack of grooming and poor coetaneous
circulation), a score of 4 indicated a severely hunched animal with a starey
coat on part of the animal body, a score of 5 indicated a severely hunched
animal with a starey coat over the entire body, a score of 6 indicated a
slightly lethargic animal, and a score of 7 indicated a lethargic animal. A
humane endpoint was set at a clinical score of 6 or 7.
Mouse survival after pneumococcal infections. Infected animals (10
animals per group) were monitored every 6 to 10 h for clinical signs until
the animal was lethargic or until day 7 postinfection. An animal still alive
at 7 days postinfection was considered a survivor, and this time point was
also a surrogate for the endpoint of the experiment. The bacterial loads in
blood were measured at 24 h postinfection and at the time when the
animal was lethargic or at the end of the experiment for survivors. At 24 h
postinfection,25 to 50l of blood was collected from the tail vein and at
the time of animal expiration by cardiac puncture under deep anesthesia
(5.0% [vol/vol] fluothane [Zeneca Pharmaceuticals, United Kingdom]
over oxygen at a rate of 1.5 to 2 liters/min). The animal was euthanized by
cervical dislocation, and the lungs were removed, weighed, placed into 10
ml of PBS, and immediately homogenized. Pneumococcal CFU were
tested in the lung homogenates on blood agar base plates (Oxoid) in serial
decimal dilutions and then converted to CFU per milligram of lung tissue.
Measurements of pulmonary cytokine levels. Infected animals (6
mice per group) were euthanized by cervical dislocation at 6 h and 24 h
postinfection, during which time no death due to infection was observed.
The lungs were immediately removed and processed by using a Bio-Plex
cell lysis kit (Bio-Rad) according to the manufacturer’s protocols. Briefly,
the lungs were immediately washed by using Bio-Plex cell wash buffer
(Bio-Rad) and then transferred to 1 ml of Bio-Plex cell lysis buffer (Bio-
Rad) with the complete protease inhibitor cocktail (Roche) for homoge-
nization. The homogenate was then centrifuged for 5 min at 10,000 g,
and the supernatant was aliquoted into cryotubes and frozen at 80°C.
The concentrations of seven cytokines were measured at each tested time
point by using enzyme-linked immunosorbent assay (ELISA) Ready-
Set-Go kits (eBioscience) for quantification of interleukin-1 (IL-1),
TABLE 1 Pneumococcal strains used in this study and their lethality in the tested inbred mouse strains BALB/c and CBA/Caa
Pneumococcal
strain Serotype
Sequence
type
Lethality
type
CBA/CA mice BALB/c mice
%
survival
Avg survival
time (h)
SEM for survival
time (h)
%
survival
Avg survival
time (h)
SEM for survival
time (h)
BS71 3 180 Lethal 10 52.8 13.3 0 28 0.0
BHN35 3 180 Lethal 0 38.4 1.6 30 104 16.1
TIGR4 4 205 Lethal 0 71.5 5.5 30 106.3 14.5
D39 2 595 Mixed 10 45.7 13.7 90 161.3 6.7
BHN418 6B 138 Mixed 30 116.2 13.3 100 168 0
BHN191 6B 138 Mixed 30 93.2 18.5 90 158.2 9.8
BS69 14 124 Nonlethal 100 168 0 100 168 0
LgtSt215 19f 179 Nonlethal 100 168 0 100 168 0
BHN100 19f 179 Nonlethal 100 168 0 100 168 0
CBR206 19f 162 Nonlethal 100 168 0 100 168 0
a Lethality type indicates pneumococcal lethality based on mortality in the tested mouse strains, where lethal indicates mortality in both mouse strains, mixed indicates lethality in
CBA/Ca mice only, and nonlethal indicates that no mortality was observed. Survival indicates the percentage of animals that survived infection. The average survival time is the
mean survival time (hours) within the group when animals survived past 168 h (end of the experiment), a surrogate time that denotes survivors.
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FIG 1 Pneumococcal burdens in tested tissues. (A) Blood at 24 h postinfection (CFU per milliliter); (B) blood at the time of animal expiration (CFU per
milliliter); (C) lung at the time of animal expiration (CFU per milligram). The pneumococcal serotypes are presented in parentheses together with the strain
name (x axis). Each experimental group consisted of 10 animals. The survival rate for each tested infection is presented at the top. For clarity, the presented
statistics represent only the differences between mouse strains. *, P 0.05; **, P 0.001; ***, P 0.0001; ****, P 0.00001.
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IL-6, IL-10, IL-17, gamma interferon (IFN-	), and tumor necrosis fac-
tor alpha (TNF-) concentrations according to the manufacturer’s pro-
tocols. The Ccl5 (RANTES) concentration was measured by using the
Quantikine ELISA kit (R&D Systems). Each sample was diluted 10-fold,
and cytokines were measured in technical triplicates. Three control sam-
ples with known cytokine concentrations were included on each microti-
ter plate. The optical density of the samples was measured by using an
Infinite F50 ELISA plate reader (Tecan), and the cytokine concentration
was calculated with GraphPad Prism using nonlinear regression. The cy-
tokine concentration was than adjusted according to the lung weight and
expressed as picograms per milligram of lung tissue.
RNA extraction and microarray assay. Mice (3 to 5 per group) were
infected with four pneumococcal strains that are known to disseminate
into lung and represent different virulence types: LgtSt215, which is non-
lethal in both mouse strains; D39 and BHN418, with host-dependent
virulence (lethal in CBA/Ca but nonlethal in BALB/c); and BS71, which is
virulent in both mouse strains. The animals were sacrificed at 6 h postin-
fection, and their lungs were removed, cut into small cubes, immediately
placed into RNAlater (Qiagen), and stored overnight at 4°C. RNA was
isolated as described previously (5); briefly, the lungs were removed from
RNAlater (Qiagen), mouse RNA was isolated by using an RNeasy minikit
(Qiagen), and cRNA was synthesized by using an Ambion MessageAmp
kit for Illumina arrays. Gene expression was measured by using Illumina
Mouse WG-6_V2_0_R3 BeadChips, and the BeadChips were scanned on
an Illumina BeadArray reader. The signal intensity was normalized (quin-
tile normalization) across all arrays by using GenomeStudio (Illumina),
and batch correction was performed by using dCHIP software (27).
Analyses ofmicroarray data. The gene expression data were analyzed
by using ArrayTrack (28), and the expected survival rate was based on the
results of previous survival experiments. Briefly, three lists of differentially
expressed genes (DEGs) were created by using a t test or analysis of vari-
ance (ANOVA) in ArrayTrack. The signal intensity ratios were compared
between infected BALB/c and CBA/Ca mice (host factor), between ani-
mals expected to survive and animals expected to die of the infection
(survival factor), and between animals infected with different pneumo-
coccal strains: BHN418-infected mice versus LgtSt215-infected mice ver-
sus D39-infected mice versus BS71-infected mice (pathogen factor). To
determine the activation of the pulmonary transcriptome by each pneu-
mococcal strain, the gene expression of infected animals was compared to
that of PBS-treated mice. A gene was considered differentially expressed
when the P value was 0.05 and the fold change was 1.5. A group of
TABLE 2 Relationship between pulmonary cytokine concentrations and different disease phenotypes or host and pathogen genetic backgrounds as
determined by a multivariate linear regression modela
Dependent variable
Predictor
Cytokines at 2 time points Cytokines at 6 h Cytokines at 24 h
Pearson R Adjusted R2 P Pearson R Adjusted R2 P Pearson R Adjusted R2 P
Lung CFU 0.903 0.791 0.0001 0.757 0.547 0.0001 0.822 0.655 0.0001
Endpoint bacteremia 0.883 0.75 0.0001 0.661 0.402 0.0001 0.808 0.63 0.0001
Survival 0.863 0.711 0.0001 0.7 0.458 0.0001 0.795 0.609 0.0001
Bacteremia at 24 h 0.793 0.579 0.0001 0.301 0.033 0.149 0.77 0.567 0.0001
Pneumococcal strain 0.874 0.731 0.0001 0.426 0.13 0.002 0.791 0.602 0.0001
Pneumococcal serotype 0.796 0.584 0.0001 0.601 0.321 0.0001 0.67 0.414 0.0001
Mouse strain 0.874 0.733 0.0001 0.752 0.538 0.0001 0.737 0.514 0.0001
a Lung CFU indicate pneumococcal counts in the lung at the time of death. Endpoint bacteremia indicates pneumococcal counts in blood at the time of death. Survival indicates
the average time (hours) that BALB/c or CBA/Ca mice survived after infection by each pneumococcal strain. Pneumococcal strains used were D39 (ST2), BS71 (ST3), BHN35
(ST3), TIGR4 (ST4), BHN191 (ST6B), BHN418 (ST6B), BS69 (ST14), BHN100 (ST19f), LgtSt215 (ST19f), and CBR206 (ST19f). Mouse strains used were BALB/c and CBA/Ca.
TABLE 3 Pulmonary cytokines that show a significant contribution in the tested multivariate linear regression modelsa
Cytokine
Time
point (h)
Variable
Survival Lung CFU Pneumococcal strain Mouse strain
Beta T Sig. Beta T Sig. Beta T Sig. Beta T Sig.
IL-1 6 0.289 2.11 0.038
IL-1 24 0.249 2.03 0.044 0.463 3.93 >0.0001
IL-6 6 0.403 3.94 >0.0001
IL-6 24 0.516 6.71 >0.0001 0.53 8.12 >0.0001 0.305 4.11 >0.0001 0.372 5.04 >0.0001
IL-10 6 0.718 3.61 >0.0001
IL-10 24 0.265 2.49 0.014 0.95 9.27 >0.0001
IL-17a 6 0.426 2.22 0.028 0.451 2.45 0.016
IL-17a 24 0.195 2.19 0.031
IFN- 6 0.339 2.08 0.04 0.303 2.19 0.031 0.492 3.14 0.002 0.988 6.31 >0.0001
IFN-	 24
TNF- 6 0.321 2.79 0.006
TNF- 24 0.303 2.39 0.019 0.238 2.20 0.03
Ccl5 6 0.302 2.97 0.004 0.624 5.42 >0.0001
Ccl5 24 0.259 3.43 0.001 0.187 2.92 0.004 0.168 2.31 0.023
a Analysis was performed by using SPSS. Boldface type indicates contribution3
 t
 3. Survival indicates the time (hours) that the animal survived infection. Lung CFU indicate
pulmonary pneumococcal counts at the time of death. Pneumococcal strains used were D39 (ST2), BS71 (ST3), BHN35 (ST3), TIGR4 (ST4), BHN191 (ST6B), BHN418 (ST6B),
BS69 (ST14), BHN100 (ST19f), LgtSt215 (ST19f), and CBR206 (ST19f). Mouse strains used were BALB/c and CBA/Ca. Beta, beta coefficient; T, t-statistics; Sig., significance
(P value).
Pulmonary Inﬂammation Is Associated with Survival
April 2016 Volume 84 Number 4 iai.asm.org 897Infection and Immunity
 o
n
 August 22, 2017 by CARDIFF UNIVERSITY
http://iai.asm
.org/
D
ow
nloaded from
 
genes was then selected to validate microarray results by using quantita-
tive PCR (qPCR) as described previously (5).
Statistical data analysis. The cytokine concentrations at 6 h and 24 h
postinfection were autoscaled, and their associations with animal survival
and pulmonary and blood CFU were tested by using multivariate regres-
sion analysis in the PASW Statistics v18 package (IBM SPSS). Principal-
component (PC) analysis (PCA) was performed by using Solo software
(Eigenvector Research Incorporated). Cytokine data were orthogonally
transformed into linearly uncorrelated coordinates and visualized after
projection onto two-dimensional (2D) and three-dimensional (3D) plots
to investigate clustering of the samples based on the expected survival
type: survivors (no pneumococcal burdens were detected, and no death
was observed), bacteremic survivors (no death was observed, although
animals were bacteremic), survivors that developed pulmonary carriage
(no death was observed, but pulmonary carriage was present), and fatal-
ities (mortality rate of 70% to 100%).
Microarray data accession number. The gene expression data were
deposited in the NCBI Gene Expression Omnibus (GEO) under accession
no. GSE61459.
RESULTS
Clinical outcome of pneumococcal infection is controlled by
both host and pathogen genetic backgrounds. Intranasal infec-
tions of two inbred mouse strains with each of the 10 tested pneu-
mococcal strains generated a wide range of clinical phenotypes
depending on the host-pathogen combination. Although a mouse
strain could generally be said to be innately resistant or susceptible
to pneumococcal infection, none was found to be resistant or
susceptible to all tested pneumococcal strains. Furthermore, the
tested pneumococcal strains could be classified into three distinct
groups based on their lethality in the tested mouse strains: (i)
highly lethal regardless of the host background, such as BS71
(ST3), BHN35 (ST3), and TIGR4 (ST4); (ii) lethal dependent on
the host background, such as D39 (ST2), BHN418 (ST6B), and
BHN191 (ST6B); and (iii) nonlethal, such as LgtSt215 (ST19f),
BHN100 (ST19F), CBR206 (ST19f), and BS69 (ST14) (Table 1).
Pneumococcal strains from the same lethality group could signif-
icantly differ in their tissue dissemination and burdens, and ani-
mals with significant differences in survival could show similar CFU
in tested tissues. For example, all animals reaching the humane end-
point (lethargic) had bacteria in their tissues, but surprisingly, pneu-
mococci were also readily detected in the tissues of mice that ap-
peared clinically normal, such as LgtSt215 (ST19f)-infected CBA/Ca
mice (Fig. 1C; see also Fig. S1 in the supplemental material) or
BALB/c mice infected with BHN418 (ST6B) or BHN191 (ST6B) (Fig.
1; see also Fig. S1 in the supplemental material). Indeed, the latter two
strains caused similar levels of bacteremia in both inbred mouse
strains (P
 0.05), yet mortality was observed only for CBA/Ca mice.
More surprisingly, the BALB/c survivors of BHN418 (ST6B) infec-
tion still had bacteremia despite recovery and clinical signs of clear-
ance (Fig. 1B). In contrast, at 24 h postinfection, BHN35 (ST3) and
BS71 (ST3) were readily detected in the blood of CBA/Ca but not
BALB/c mice (Fig. 1A), although both mouse strains displayed high
mortality rates (70% to 100%).
Pulmonary inflammation is related to host and pathogen ge-
netic backgrounds and pulmonary CFU but is not associated
with development of bacteremia at 24 h. To begin to explain the
high level of variation in pneumococcal dissemination and animal
mortality following infections with different pneumococcal
strains, the pulmonary concentrations of seven cytokines were
measured at 6 h and 24 h postinfection. Within this time window,
infected animals displayed signs of disease, but no mortality was
yet observed (see Fig. S1 in the supplemental material). Following
pneumococcal infections, all tested animals showed changes in the
levels of at least some of the tested cytokines, but no clear pattern
was identified. Therefore, pulmonary cytokine concentrations
were analyzed by using a multivariate linear regression model
(MLRM) to identify relationships between pulmonary cytokines
and pneumonia phenotypes such as survival, lung CFU, bactere-
mia at 24 h, and host and pathogen genetic backgrounds. The early
pulmonary cytokine profile showed significant associations with
pulmonary bacterium counts at the time of animal expiration
(when animals were lethargic or at 168 h postinfection) and with
average survival time but not bacteremia at 24 h postinfection.
Interestingly, even the cytokine profile measured at 24 h postin-
fection showed a poor relationship with bacteremia at 24 h (Table
2). Depending on the tested trait, different cytokines contributed
to the regression model, and only two cytokines, IL-6 at 24 h
postinfection and IFN-	 at 6 h postinfection, had a significant
contribution to the regression model for all tested traits (Table 3).
Variation in pulmonary cytokine profiles is associated with
variation in animal survival. We applied another statistical ap-
proach to test the association between early pulmonary inflamma-
tion and tested traits. Cytokine concentrations were analyzed by
using PCA (Table 4), and PC scores were plotted on a two- or
three-dimensional diagram to visualize clustering of the samples.
The PCA model based on the cytokine profile at 6 h postinfection
efficiently discriminated resistant from susceptible mice using two
PCs that captured 77% of the total variance (Fig. 2A). The cyto-
kine profile at 24 h postinfection predicted animal survival based
on the scores for three PCs that captured 62% of the total variance
in the model, but the bacteremic survivors were incorrectly clas-
TABLE 4 PCA of pulmonary cytokine concentrations at 6 h and 24 h postinfectiona
PC
Cytokines at 2 time points Cytokines at 6 h Cytokines at 24 h
%
variance
Cumulative
% variance
Eigen value
of Cov(X)
%
variance
Cumulative
% variance
Eigen value
of Cov(X)
%
variance
Cumulative
% variance
Eigen value
of Cov(X)
1 41.1 41.1 5.8 73.7 73.7 5.2 40.7 40.7 2.9
2 20.5 61.5 2.9 14.2 87.9 1.0 26.9 67.7 1.9
3 11.7 73.2 1.6 5.5 93.4 0.4 15.7 83.4 1.1
4 8.5 81.7 1.2 3.6 97.0 0.3 6.8 90.2 0.5
5 5.5 87.2 0.8 5.9 96.1 0.4
6 3.4 90.6 0.5
7 3.0 93.7 0.4
a Percentages of the variance captured by the PC, cumulative variance, and Eigen values are presented. Cov(X), covariance of x.
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FIG 2 Association of mouse pulmonary inflammation with survival during pneumococcal infection. PCA plots were generated by using the cytokine concen-
trations measured at a single time point, 6 h (A) or 24 h (B) postinfection, or at both time points (C). The percentage of the variation captured by each PC is
presented. Each data point represents one animal.
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FIG 3 Pulmonary inflammation predicts survival of the test animals. The PCA model was validated by using lung samples of the animals previously excluded
from the model. The animals from the test set (excluded) are represented by symbols with a fadeout effect. The data points for both the calibration and validation
sets (fadeout colors) are presented together on the plot for better visualization of the position of the test samples within tested survival types. Each data point
represents one animal. Validation using the cytokine concentrations at 6 h (A), at 24 h (B), and at both tested time points (C) is presented. The percentage of the
total variation captured by the PC is shown. The genetic background of each data point is demonstrated at the right (A1 to C1).
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sified as fatalities (Fig. 2B). The cytokine data from both time
points were then analyzed, and animal survival was correctly pre-
dicted using three PCs that captured 56% of the total variance
(Fig. 2C). Indeed, the cytokine concentrations at the two time
points during infection discriminated best between survivors and
fatalities, with survivors that developed pulmonary carriage being
placed in a separate cluster.
Next, we validated the PCA model using a set of test samples,
which included sham-infected animals and C57BL/6J mice in-
fected with the D39, BS71, and BHN35 strains. The PCA models
predicted correctly the expected survival of the animals in the test
group, regardless of the host and pneumococcal genetic back-
grounds (Fig. 3A to C).
High mortality rates are associated with pneumococcal eva-
sion of hostmolecular responses, which depend on host genetic
background. To understand the impact of the pneumococcal ge-
netic background on the molecular responses in the lungs of tested
mouse strains, we investigated changes in the pulmonary tran-
scriptome at 6 h postinfection. The pulmonary transcriptomes of
infected and PBS-treated mice were compared during infections
with four pneumococcal strains, each causing different disease
pathologies: LgtSt215 (ST19f) (nonlethal but readily detected in
the lung), BS71 (ST3) (lethal in both mouse strains), and BHN418
(ST6B) and D39 (ST2), which have host-dependent lethality. The
obtained lists of differentially expressed genes (DEGs) were then
analyzed by using the DAVID online tool. Interestingly, the tran-
scriptomic response was particularly weak in animals that showed
high mortality rates (except for D39-infected CBA/Ca mice). The
pulmonary transcriptomes of fatalities showed lower numbers of
differentially expressed genes as well as fewer and less significant
enrichment in biological themes and functionally related gene
groups (Table 5). Indeed, the most severe disease caused by BS71
infection of BALB/c mice was associated with an almost complete
lack of transcriptomic responses in the lung at 6 h postinfection
(Table 5). However, D39-infected CBA/Ca mice did not fit the
molecular pattern observed for other fatalities. Instead, their pul-
monary transcriptome was similar to the one observed for nonle-
thal infections. However, in contrast to the survivors, D39-in-
fected CBA/Ca mice showed significant enrichment in genes
related to T-cell receptor signaling and natural killer cell-mediated
cytotoxicity but not the hematopoietic cell linage pathway (Table
5) (5). Furthermore, we also took a closer look at the cytokine-
cytokine receptor signaling pathway (KEGG) to identify any
potential differences between fatalities and survivors of pneu-
mococcal infections. We found that some of the receptors were
differentially expressed during all or most pneumococcal infec-
tions regardless of their clinical outcome (e.g., Cxcl1, IL13RA1,
Ccl19, IL1A, and IL1B), many were identified in a few tested in-
fections (without a clear association with animal survival), and
only one gene was found uniquely in nonlethal infections:
CSF2RA (involved in pulmonary surfactant metabolism).
Lung innate immunity is jointly influenced by host and
pathogen genetic backgrounds. We were then interested in the
impact of host-pathogen interactions on the pulmonary tran-
scriptome and its effect on animal survival. Three lists of DEGs
were obtained by comparing (i) expected survivors and expected
fatalities of pneumococcal infections (survival factor), (ii) in-
fected BALB/c and infected CBA/Ca mice (host factor), and (iii)
BHN418 (ST6B)-infected mice versus LgtSt215 (ST19f)-infected
mice versus D39 (ST2)-infected mice versus BS71 (ST3)-infected
mice (pathogen factor).
Next, the three lists of DEGs were compared against each other
to identify genes present in more than one list. We found that
virtually all the DEGs associated with the survival factor were also
TABLE 5 Signaling pathways during infection with different pneumococcal strainsa
Pathway
P value
BALB/c mice CBA/Ca mice
D39 (ST2)
BHN418
(ST6B)
LgtSt215
(ST19f)
BS71 (ST3)
(lethal)
D39 (ST2)
(lethal)
BHN248 (ST6B)
(lethal)
LgtSt215
(ST19f)
BS71 (ST3)
(lethal)
Cytokine-cytokine receptor interaction 3.92E07 9.10E07 3.70E07 2.38E08 5.30E04 8.20E04 7.20E03
Toll-like receptor signaling pathway 3.32E04 7.70E06 3.20E05 1.33E06 1.00E03 1.60E07 3.30E02
Chemokine signaling pathway 9.02E03 3.20E04 7.80E04 5.10E05 2.30E05
MAPK signaling pathway 1.93E05 4.30E02 1.30E03 1.08E04 1.20E02 1.10E02
B-cell receptor signaling pathway 3.10E03 1.30E02 2.00E03 4.43E05 5.40E04
Hematopoietic cell lineage 1.20E03 3.40E03 4.40E04 3.00E03 3.20E03 3.00E04
Apoptosis 1.57E03 4.10E03 3.00E03 1.09E04 8.40E02 4.00E03 2.40E02
Pathways in cancer 2.92E05 2.60E02 4.00E02 6.33E07
Adipocytokine signaling pathway 6.20E03 7.80E04 1.56E04 7.40E04
Jak-STAT signaling pathway 1.88E04 1.70E02 1.30E02 3.02E03 5.20E03
NOD-like receptor signaling pathway 8.63E03 2.30E02 5.88E03 3.60E02
Cytosolic DNA-sensing pathway 1.05E02 5.40E03
Natural killer cell-mediated cytotoxicity 9.83E04
Prion diseases 2.60E02
Fc gamma R-mediated phagocytosis 8.20E03
Axon guidance 3.92E03
Complement and coagulation cascades 1.60E02
Alzheimer’s disease 4.00E02
p53 signaling pathway 4.33E03
T-cell receptor signaling pathway 6.06E03
a Gene expression was evaluated by comparison of infected mice and PBS-treated mice. The significance (P value) of each pathway is presented.
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associated with either the host or the pathogen factor (Fig. 4).
Therefore, we hypothesized that the DEGs important for survival
and whose expression also differed between different pneumococ-
cal infections represented the pneumococcal contribution to dif-
ferences in animal survival. Likewise, the DEGs important for sur-
vival and whose expression also differed between infected BALB/c
and CBA/Ca mice represented host impact on survival. A subse-
quent functional analysis of the overlapping (shared) genes that
were associated with the survival and pathogen factors showed
significant enrichment in genes important for pathogen recogni-
tion (enriched pathways included cytosolic DNA sensing, Toll-
like receptor, and NOD and mitogen-activated protein kinase
[MAPK] signaling) as well as immune cell activation and migra-
tion (B- and T-cell signaling and taxis). On the other hand, genes
whose expression differed between survivors and fatalities of
pneumococcal infections as well as between infected BALB/c and
CBA/Ca mice were related to the complement system, hematopoi-
esis, and cytokine signaling (Tables 6 and 7). Interestingly, expres-
sion of the genes important for antigen processing and presenta-
tion and for cell adhesion differed between BALB/c and CBA/Ca
mice but not between survivors and fatalities. Similarly, expres-
sions of the genes important for vasculature function, pathogen
recognition, and chemokine and adipocytokine signaling differed
between different pneumococcal infections but not between ani-
mals displaying different survival types (Tables 6 and 7).
DISCUSSION
Streptococcus pneumoniae (pneumococcus) is a common com-
mensal of the human nasopharynx and a cause of a high morbidity
and mortality rates. Pneumococcal infections characterize diverse
inflammatory responses influenced by host and pathogen genetic
backgrounds. Previous studies also demonstrate that cytokines
affect the clinical outcome of pneumococcal infection (16–18),
and immunomodulation has a beneficial effect on the survival of
susceptible animals (24). Unfortunately, these results are largely
derived from “one-host, one-pathogen” models and therefore do
not provide information on how host and pathogen genetic vari-
ations affect inflammation and clinical outcome. To improve
management of pneumococcal disease, it is essential to better un-
derstand the relationship among cytokines, host and pathogen
genetic diversity, and mortality from pneumonia.
In our study, we selected two inbred mouse strains, BALB/c
and CBA/Ca (4, 5), and tested their susceptibility to infection with
FIG 4 Similarities between the lists of DEGs. The lists of DEGs were generated
by comparison of infected BALB/c versus infected CBA/Ca mice (host factor),
mice infected with different pneumococcal strains (pathogen factor), and sur-
vivors versus fatalities of pneumococcal infections (survival factor). The num-
ber of DEGs identified in each comparison as well as the number of overlap-
ping genes are presented.
TABLE 6 Comparative pathway analysis (DAVID) of DEGsa
KEGG pathway
Shared genes Unique genes
Mouse P
value
Pneumococcus
P value
Mouse
P value
Pneumococcus
P value
Complement and coagulation cascades 8.00E05
Systemic lupus erythematosus 3.30E03
Hematopoietic cell lineage 0.01
Cytokine-cytokine receptor interaction 0.02 1.00E03
Allograft rejection 0.05
NOD-like receptor signaling pathway 7.30E04
Pathways in cancer 1.90E03
Cytosolic DNA-sensing pathway 0.01
B-cell receptor signaling pathway 0.02
Toll-like receptor signaling pathway 0.03 4.90E05
MAPK signaling pathway 0.04
T-cell receptor signaling pathway 0.05
Chemokine signaling pathway 1.20E03
Leukocyte transendothelial migration 4.50E03
Adipocytokine signaling pathway 0.03
Cell adhesion molecules 0.05 0.05
Antigen processing and presentation 0.05
Base excision repair 0.05
a Shared genes indicate the list of genes associated with both survival and either mouse strain or pneumococcal strain. Unique genes indicate the list of genes associated with only
one of the studied factors: host (mouse) or pneumococcal strain. The significance (P value) of each pathway is presented.
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10 pneumococcal strains representing different pneumococcal se-
rotypes. This approach generated a wide range of pneumonia phe-
notypes, enabling comprehensive analysis of host-pathogen inter-
actions and mortality from pneumonia. We determined that the
variation in disease pathology, host susceptibility, and pneumo-
coccal virulence strongly depended on the host-pathogen combi-
nation. To better understand the underlying biological mecha-
nism of the observed differences, we investigated the host
pulmonary transcriptome and pulmonary cytokine production.
Our results show that most of the fatalities of pneumococcal in-
fection displayed an attenuated molecular response in the lung,
with the most lethal pneumococcal strains also being the poorest
activators of the pulmonary transcriptome. However, this was not a
universal pattern, since infection of CBA/Ca mice with pneumococ-
cal strain D39 (ST2), which resulted in a high mortality rate, was
associated with significant changes in the pulmonary transcriptome
similar to those observed in survivors. The noted exception was a
significantly higher enrichment of genes involved in the regulation of
T-cell populations in D39-infected CBA/Ca mice. Interestingly, de-
spite the observed evasion of host immunity during lethal pneumo-
TABLE 7 Comparative GO analysis (DAVID) of DEGsa
GO term
Shared genes Unique genes
Mouse P value Pathogen P value Mouse P value Pathogen P value
Immune response 2.30E07 1.40E02 1.10E07
Immune effector process 2.70E05 1.40E03
Defense response 1.10E03 2.30E04
Positive regulation of immune response 3.80E03 8.40E03
Response to cytokine stimulus 9.90E03 2.00E03
Leukocyte-mediated immunity 8.10E04
Positive regulation of response to stimulus 1.80E03
Immunoglobulin-mediated immune response 3.20E03
B-cell-mediated immunity 3.50E03
Lymphocyte-mediated immunity 5.50E03
Adaptive immune response 7.20E03
Adaptive immune response based on somatic
recombination of immune receptors built from
immunoglobulin superfamily domains
7.20E03
Negative regulation of molecular function 2.00E07
Negative regulation of catalytic activity 3.10E04
Chemotaxis 4.20E04 3.10E07
Taxis 4.20E04 3.10E07
Cell chemotaxis 3.40E03
Leukocyte chemotaxis 3.40E03
Locomotory behavior 7.30E03 2.20E04
Leukocyte migration 8.50E03 5.90E03
Behavior 9.60E03 5.40E04
Negative regulation of kinase activity 5.90E04
Negative regulation of protein kinase activity 5.90E04
Negative regulation of transferase activity 6.60E04
Negative regulation of myeloid cell differentiation 2.10E03
Negative regulation of transcription factor activity 2.30E03
Negative regulation of cell differentiation 2.80E03 3.80E03
Negative regulation of DNA binding 3.20E03
Negative regulation of binding 4.20E03
Antigen processing and presentation 2.90E03
Response to molecule of bacterial origin 1.10E07
Inflammatory response 1.40E06
Response to lipopolysaccharide 2.90E06
Vasculature development 5.50E06
Response to wounding 7.10E06
Regulation of cell proliferation 1.40E05
Angiogenesis 1.60E05
Response to organic substance 1.60E05
Blood vessel development 1.80E05
Positive regulation of cell differentiation 4.30E05
Positive regulation of immune system process 4.90E05
Positive regulation of developmental process 7.30E05
Response to bacterium 7.40E05
Regulation of tumor necrosis factor production 7.90E05
a Shared genes indicate the list of genes associated with both survival and either mouse strain or pneumococcal strain. Unique genes indicate the list of genes associated with only
one of the studied factors: host (mouse) or pneumococcal strain. The significance (P value) of each GO term is presented.
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coccal infections, we still detected significant changes in the pulmo-
nary cytokine profile in all tested pneumococcal infections except for
the BS71 (ST3) strain at 6 h postinfection. However, the observed
cytokine responses significantly differed between tested pneumococ-
cus-host combinations and during the course of the disease. There-
fore, to identify a biologically relevant pattern(s), the obtained cyto-
kine data were analyzed by multivariate data analysis.
Multivariate regression analysis identified two cytokines, IL-6
and IFN-	, that significantly contributed to all tested regression
models (host, pathogen, lung CFU, or survival) but only at a single
time point during infection (at 24 h and 6 h postinfection for IL-6
and IFN-	, respectively). The role of IL-6 and IFN-	 in pneumo-
nia was previously described (22, 29), yet it remains unclear how
they affect survival. For example, significant reductions in disease
severity and pneumococcal blood invasion were observed during
serotype 3 infection of mice deficient in CXCR3, a common re-
ceptor for IFN-	-inducible chemokines such as Cxcl9, Cxcl10,
and Cxcl11 (30). The role of IFN-	 during pneumococcal infec-
tion was also demonstrated in another study (29), which showed
that IFN-	-deficient mice exhibit significantly lower pulmonary
pneumococcal counts, supporting the role of cytokines in the reg-
ulation of pneumococcal growth. However, the observed reduc-
tion in pneumococcal counts did not improve animal survival,
therefore suggesting that changes in pneumococcal tissue burdens
did not translate to a modification of the clinical outcome (29).
Indeed, this conclusion was also supported by our results, which
showed significant differences in pneumococcal tissue burdens in
animals with similar survival rates, while no differences in CFU
were observed for survivors and fatalities for some of the tested
pneumococcal infections. Furthermore, in our study, infection
with a serotype 3 strain did not activate IFN-	 production. We
even observed a decrease in the level of pulmonary IFN-	 detected
in PBS-treated mice. Subsequently, there was no expression of the
IFN-	-inducible chemokines in both BALB/c and CBA/Ca mice at
6 h postinfection. However, the absence of pulmonary IFN-	 at 6
h post-BS71 (ST3) infection was not associated with lower pneu-
mococcal numbers or reduced disease severity in our study. Quite
the opposite, both tested mouse strains exhibited high mortality
rates and high pulmonary CFU. We also observed differences be-
tween BALB/c and CBA/Ca mice in serotype 3 blood invasion,
with BALB/c blood being largely sterile and CBA/Ca mice devel-
oping high-level septicemia, indicating that the absence of IFN-	
did not influence BS71 (ST3) blood dissemination. Interestingly,
IFN-	 is associated with T-cell populations, and our gene expres-
sion analysis showed that genes associated with T-cell functioning
were significantly enriched in the pulmonary transcriptome of
CBA/Ca mice during lethal infection with D39 (ST2) but not in
the pulmonary transcriptome of survivors.
We then hypothesized that the cytokine profile rather than a
single inflammatory mediator is a hallmark of a beneficial or path-
ological inflammatory process. To test this hypothesis, we used
principal-component analysis to investigate clustering of the sam-
ples based on their inflammatory profile. Using this approach, we
achieved good separation of tested samples according to their sur-
vival type but not according to the mouse or pneumococcal strain
used in the infection. The pulmonary cytokine profile at 6 h
postinfection discriminated better between survivors and fatali-
ties than did the cytokine profile detected 18 h later, at the 24-h
time point. The cytokine profile at 24 h misclassified the bactere-
mic survivors within the susceptible group. However, when cyto-
kine concentrations at two time points were analyzed, the discrim-
ination between survivors and fatalities improved. Although the
PCA model was calibrated based on the cytokine concentrations
in CBA/Ca and BALB/c mice, it was successfully used to predict
the survival type of another inbred mouse strain, C57BL/6J, after
pneumococcal infection. This result strongly supported the con-
clusion that the cytokine profile reflects protective or pathological
inflammatory responses.
The PCA model was previously applied in a study of tubercu-
losis to determine the association of pulmonary inflammation
with patient ethnicity or Mycobacterium tuberculosis lineage (31).
That study went on to demonstrate that pulmonary inflammation
was associated with patient ethnicity but not Mycobacterium tu-
berculosis lineage (31). Similarly, in our study, we observed that
the cytokine profile was not associated with the pneumococcal
strain, but instead, we showed that it was associated with animal
survival. Although the relationship between pulmonary inflam-
mation and clinical outcome was not investigated and all patients
received antimicrobial therapy in the above-mentioned tubercu-
losis study, the differences in disease progress, response to the
antibiotic, and M. tuberculosis clearance were reported to be asso-
ciated with patient ethnicity. This observation indicates that eth-
nicity and clinical outcome were strongly correlated.
The results of this study demonstrate that host-pneumococcus
interactions are responsible for the observed variations in pneu-
monia phenotypes, host susceptibility, and pneumococcal viru-
lence. Despite the observed variation in pulmonary inflammation,
the generated cytokine profiles display either beneficial or patho-
logical characteristics. We also propose that the effects of a single
inflammatory mediator on animal survival may depend on the
inflammatory context and therefore might not be suitable to reli-
ably predict clinical outcomes of pneumococcal infection.
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